» Articles » PMID: 18583976

Conflicting Evidence on the Frequency of ESR1 Amplification in Breast Cancer

Overview
Journal Nat Genet
Specialty Genetics
Date 2008 Jun 28
PMID 18583976
Citations 13
Authors
Affiliations
Soon will be listed here.
Citing Articles

Novel Treatment Strategies for Hormone Receptor (HR)-Positive, HER2-Negative Metastatic Breast Cancer.

Ferro A, Campora M, Caldara A, De Lisi D, Lorenzi M, Monteverdi S J Clin Med. 2024; 13(12).

PMID: 38930141 PMC: 11204965. DOI: 10.3390/jcm13123611.


Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer.

Basudan A, Priedigkeit N, Hartmaier R, Sokol E, Bahreini A, Watters R Mol Cancer Res. 2018; 17(2):457-468.

PMID: 30355675 PMC: 6359977. DOI: 10.1158/1541-7786.MCR-18-0946.


New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response.

Rangel N, Forero-Castro M, Rondon-Lagos M Genes (Basel). 2017; 8(6).

PMID: 28587191 PMC: 5485519. DOI: 10.3390/genes8060155.


Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.

Chen J, Chien H, Chen K, Hwang C, Chen H, Yeh K Medicine (Baltimore). 2017; 96(2):e5582.

PMID: 28079792 PMC: 5266154. DOI: 10.1097/MD.0000000000005582.


Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate.

Holst F World J Clin Oncol. 2016; 7(2):160-73.

PMID: 27081639 PMC: 4826962. DOI: 10.5306/wjco.v7.i2.160.